

11 July 2022

*The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.*

**OMEGA DIAGNOSTICS GROUP PLC**  
("Omega" or the "Company" or the "Group")

**Payment received**

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces that it has received payment from Abingdon Health plc ("Abingdon") in relation to the manufacture and supply of AbC-19™ Rapid tests, a COVID-19 lateral flow antibody test.

The payment was due under the Supply of Goods contract announced on 19 October 2020, and was made following confirmation from Abingdon that a cash payment had been received from the Department for Health & Social Care ("DHSC") on 7 July 2022, as part of a settlement agreement relating to outstanding invoices due from DHSC to Abingdon.

**Contacts:**

**Omega Diagnostics Group PLC**

Jag Grewal, Chief Executive Officer  
Chris Lea, Chief Financial Officer

[www.omegadx.com](http://www.omegadx.com)  
via Walbrook PR

**finnCap Ltd**

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)  
Alice Lane/ Harriet Ward (ECM)

Tel: 020 7220 0500

**Walbrook PR Limited**

Paul McManus  
Lianne Applegarth  
Sam Allen

Tel: 020 7933 8780 or [omega@walbrookpr.com](mailto:omega@walbrookpr.com)  
Mob: 07980 541 893  
Mob: 07584 391 303  
Mob: 07502 558 258

**About Omega Diagnostics Group PLC**

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.

[www.omegadx.com](http://www.omegadx.com)